The Legacy Heritage Oncology Center & Dr. Larry Norton Institute Soroka Medical Center & Ben-Gurion University Beer-Sheva Israel;
Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel;
The Legacy Heritage Oncology Center & Dr. Larry Norton Institute Soroka Medical Center & Ben-Gurion University Beer-Sheva Israel;
The Legacy Heritage Oncology Center & Dr. Larry Norton Institute Soroka Medical Center & Ben-Gurion University Beer-Sheva Israel;
Faculty of Health Sciences Ben-Gurion University of the Negev Beer-Sheva Israel;
The Legacy Heritage Oncology Center & Dr. Larry Norton Institute Soroka Medical Center & Ben-Gurion University Beer-Sheva Israel;
Rabin Medical Center Beilinson Campus Petah Tikva Israel;
The Legacy Heritage Oncology Center & Dr. Larry Norton Institute Soroka Medical Center & Ben-Gurion University Beer-Sheva Israel;
The Legacy Heritage Oncology Center & Dr. Larry Norton Institute Soroka Medical Center & Ben-Gurion University Beer-Sheva Israel;
The Legacy Heritage Oncology Center & Dr. Larry Norton Institute Soroka Medical Center & Ben-Gurion University Beer-Sheva Israel;
ROS1; Crizotinib; Squamous Cell Lung Cancer; Immunotherapy; Non-Small Cell Lung Cancer;